Stephanie L. Safgren

机构：Mayo Clinic, WinnMed, Phoenix (United States), Mayo Clinic in Arizona, Mayo Clinic in Florida · ORCID：0000-0002-5503-7324

发表论文 110 篇 · 总被引 3956 次 · h-index 25

代表论文

• Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes (2023 · iScience · 被引 38)
• De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity (2024 · Brain · 被引 12)
• Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial (2025 · Clinical Cancer Research · 被引 10)
• First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort. (2023 · Journal of Clinical Oncology · 被引 6)
• The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen (2025 · Breast Cancer Research and Treatment · 被引 3)
• Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data (2024 · Human Genetics · 被引 2)